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Nausea is a subjective unpleasant sensation, associated with an urge to vomit. 
Vomiting is a forceful expulsion of gastric contents through the mouth, which involves 
elevation of the soft palate, relaxation of pharyngeal muscles, descent of diaphragm as well as 
contractions of the abdominal and respiratory chest muscles. 
Retching, which usually comes before vomiting, is associated with activation of the same 
muscles, however without expulsion of any stomach contents (Andrews 1992; Apfel et al. 
2002). 
Postoperative Nausea and Vomiting (PONV) is often defined as any nausea and/or 
retching/vomiting 24-28h after surgery (Pierre and Whelan 2013). For the studies on PONV 
Apfel et al. recommend to limit the observation period to 24 h. Additionally PONV can be 
classified into early (0-2h) and delayed (2-24h) PONV (Apfel et al. 2002). 
 Postoperative Nausea and Vomiting 
Despite the advances in anesthesiology, postoperative nausea and vomiting (PONV) with 
its complex aetiology still remains a common postoperative complication among many patients. 
 PONV occurs in 20-30% of all surgical patients when balanced anaesthesia techniques are 
used without pharmacological prophylaxis and in up to 80% of the patients with multiple risk 
factors (Gan et. al 2014, Watcha and White 1992). Even though PONV is often considered a 
big “little” problem (Kapur 1991), it may lead to severe complications including dehydration, 
electrolyte imbalances, aspiration pneumonia, oesophageal rupture, wound dehiscence, 
subcutaneous emphysema, pneumothorax and loss of vision (Apfel et al. 2012). PONV is 
undoubtedly a distressing complication for patients, leading to dissatisfaction associated with 
general anaesthesia (Eberhart et al. 2002). Moreover, it poses an economic burden due to a 
protracted stay in the recovery room after operation, delays in discharge, additional antiemetic 





Several studies investigating which risk factors could be independent predictors of PONV 
showed that it is associated with patient-specific (female gender, nonsmoking status, history of 
PONV and/or motion sickness, younger age) or anaesthesia-related (use of volatile anaesthetics 
and/or nitrous oxide, postoperative opioid use, duration of anaesthesia) risk factors. While 
female gender is the strongest patient specific risk factor, the use of volatile anaesthetics is the 
strongest anaesthesia-related predictor for PONV. Certain types of surgery such as bariatric, 
gynecological, laparoscopic surgery and cholecystectomy may be linked to an increased risk of 
PONV (Gan et al. 2020). With development of the simplified risk scores, such as Apfel score 
(female gender, history of PONV and/or motion sickness, nonsmoking and postoperative opioid 
use) and Koivuranta’s score (female gender, history of PONV and/or motion sickness, 
nonsmoking and duration of surgery), which have been most widely used to assess patient’s 
individual risk of PONV, more attention has been drawn to the problem of PONV in clinical 
practice (Apfel et al. 1999, Apfel et al. 2012, Koivuranta et al. 1997).  
The incidence of PONV in patients with none, one, two, three or four Apfel score risk 
factors is 10%, 21%, 39%, 61%, 79% respectively (Apfel et al. 1999). Current guidelines 
recommend baseline risk assessment for PONV through a validated risk score. Patients with 
one or more risk factors for PONV should be identified early and a multimodal management 
consisting of both pharmacological and non-pharmacological (baseline risk reduction) 
strategies should be adopted. A decrease in the baseline risk can be achieved through several 
means. These include avoiding general anaesthesia in favor of a regional one when possible, 
use of propofol and avoidance of volatile anaesthetics and nitrous oxide, adequate hydration, 
reduction in intraoperative and postoperative opioid use and substituting neostigmine with 
suggammadex for the reversal of neuromuscular blockade (Gan et al. 2020). 
 Pathophysiology 
Mechanisms underlying PONV are very complex and so far not fully understood. While 
vomiting is an autonomic reflex, nausea requires conscious perception involving cerebral cortex 
(Apfel 2005). 
The main area responsible for coordinating vomiting, a so-called vomiting centre, is located 
within the brain stem in the medulla oblongata (Andrews 1992). However, since the exact 
location of the neurons integrating afferent information and producing an efferent response 
resulting in emesis is not known, recently the concept of a central pattern generator (CPG), 




some nuclei in the area of the reticular formation, as well as the respiratory nuclear groups, are 
believed to act as command neurons that activate CPG to generate an emetic response (Horn et 
al. 2014). 
Four main pathways activating vomiting through direct projections to the nucleus tractus 
solitarii (NTS) can be distinguished, namely the vagal afferent fibres of the gastrointestinal 
tract, the vestibular labyrinth system in the inner ear, the forebrain and the area postrema (Horn 
et al. 2014).  
Toxic stimuli or drugs lead to a release in serotonin from the enterochromaffin cells of the 
gastrointestinal tract, which then binds to the 5-hydroxytryptamine (5-HT3) receptors and 
stimulates vagal afferent neurons (Gan 2007). The vestibular system receives stimuli that 
trigger motion sickness, while the forebrain is associated with both ictal vomiting (through 
activation of the insular cortex and temporal lobe, including the amygdala) as well as seizures 
and psychogenic vomiting (Horn et al. 2014). Located in the area postrema on the floor of the 
fourth ventricle, the Chemoreceptor trigger zone (CTZ) lacks a blood-brain barrier, which 
allows it to detect emetic drugs and toxins both in the blood and in the cerebrospinal fluid (Gan 
2007, Apfel 2005). CTZ not only contains receptors for neurotransmitters such as serotonin, 
dopamine, histamine, acetylcholine and neurokinin, which are the targets of modern 
antiemetics, but also μ-opioid receptors which can explain the opioid induced emesis (Gan 
2007). Furthermore, peripheral effects of opioids as well as inhalational anaesthetics induce 
disruption of gastrointestinal function, additionally contributing to postoperative nausea and 
vomiting (Horn et al.2014). 
 Pharmacological prophylaxis and treatment 
1.4.1 Overview 
According to the most recent Fourth Consensus Guidelines for the management of 
postoperative nausea and vomiting, published in 2020, multimodal pharmacological 
prophylaxis is advised for patients with one or more risk factors for PONV, being one of the 
major changes in the management of PONV since the 2014 Guidelines (Gan et al. 2020).  
The main classes of antiemetic drugs include 5-hydroxytryptamine (5-HT3) receptor 
antagonists (granisetron, ondansetron), corticosteroids (dexamethasone), neurokinin-1 (NK-1) 
receptor antagonists (aprepitant, fosaprepitant), anticholinergics (scopolamine), antihistamines 




droperidol) (Gan et al. 2020). Generally, each of those classes shows similar efficacy in 
reducing the absolute risk of PONV by 25%, combining different antiemetic drug classes has 
an additive effect in PONV risk reduction (Gan et al. 2014).  
The main classes of antiemetic drugs, their receptor affinities, doses, time and route of 




Table 1. Main classes of antiemetic drugs (Adapted from Watcha and White 1992, Gan, 2020). 
Antiemetic group 
Receptor affinity Dosis and dry 
administration 
Time of 
administration D2 M1 Histamine 5HT3 NK1 
Corticosteroids 
– – – – – 
 
4-8 mg iv 
40 mg iv 




– – – ++++ – 
 
End of surgery 
 Granisetron 0,35-3 mg iv 
 Ondansetron 4 mg iv, 8 mg PO 
 Palonsetron 0,075 mg iv 
 Tropisetron 2 mg iv 
 Dolasetron 












1 mg/kgbw iv 
6,25 mg 




    ++++ 
 
40 mg PO 
150 mg PO 







+ ++++ + – – 
1 mg/24h (trans-dermal 
patch) 
Prior evening or 2 
































5 mg iv 
10 mg iv 
0,625 mg iv 
0,5-2 mg iv/im 

















The most commonly used and best-studied corticosteroid for the management of PONV is 
dexamethasone. Dexamethasone’s mechanism of action is complex and not yet fully known. 
One can speculate on its anti-inflammatory potential, resulting in a decrease in arachidonic acid 
and the release of inflammatory mediators release with subsequent nerve sensitization to 
neurotransmitters involved in the emesis could be responsible for its antiemetic properties. 
Apart from the central effects in the NTS, it may also directly inhibit the 5-HT3 receptors (Horn 
et al. 2014). Moreover, a single iv dexamethasone dose reduces postoperative pain and need for 
opioid use, which might also contribute to its antiemetic potential (Waldron et al. 2013, Gan et 
al. 2020). Current Guidelines recommend a 4-10 mg prophylactic dose of dexamethasone 
administered intravenously at the beginning of the surgery (Gan et al. 2020). Even though long-
term steroid treatment is associated with severe side effects, such as hypertension, diabetes, 
osteoporosis, increased infection risk and adrenal insufficiency, adverse effects of a single 
antiemetic dose are rarely reported. A recent Cochrane meta-analysis found that dexamethasone 
doesn’t contribute to postoperative wound infection and the increase in glucose levels observed 
after intravenous injection is mild even in patients with diabetes (Polderman et al.2018, Gan et 
al. 2020). Other corticosteroids, such as methylprednisolone appear to have a comparable 
efficacy to dexamethasone in PONV reduction and also show opioid-sparing effects (Gan et al. 
2020). Low cost and good safety profile make dexamethasone an attractive first-line antiemetic 
(Apfel et al. 2004). 
1.4.3 5-hydroxytryptamine (5-HT3) receptor antagonists 
5-HT3 receptor antagonists constitute one of the most the most widely used antiemetics, 
both for prophylaxis and treatment of PONV. Their mechanism of action most likely involves 
5-HT3 receptor antagonism both centrally in the area postrema as well as peripherally in the 
vagal afferents located in the gut (Horn et al. 2014). 
Ondansetron, considered the “gold standard“ in PONV prevention and therapy, is the most 
frequently used and best-studied representative of this pharmacological group (Gan et al. 2020). 
Its efficacy was shown to be similar to dexamethasone 4 mg, droperidol 1,25 mg, while 
granisetron 1-3 mg IV, ramosetron 0.3 mg IV, palonosetron 0.075 mg, fosaprepitant 150 mg 
IV and aprepitant 80 mg PO were superior to ondansetron in the management of PONV (Apfel 




Dolasetron, a highly selective 5-HT3 receptor antagonist, is recommended by the current 
guidelines in a 15,5 mg IV dose at the end of anaesthesia with efficacy similar to that of 
ondansetron. In 2010 the FDA banned the use of dolasetron for Chemotherapy-Induced Nausea 
and Vomiting (CINV) due to the risk of QT prolongation and severe cardiac arrhythmias, 
however its use in PONV, where lower doses are administered, was not contraindicated (FDA 
Drug Safety Communication 2010). 
Granisetron exerts similar efficacy to the first generation of 5-HT3 receptor antagonists as 
well as dexamethasone 8 mg and its use is recommended in the 0.35- 
3 mg dose range at the end of surgery (Gan et al. 2020). 
Tropisetron, a highly competitive and selective representant of this group found its 
antiemetic use mostly in the CINV treatment. A 2 mg IV dose at the end of surgery is 
recommended for preventing PONV. Tropisetron is not approved in the USA, but still used in 
Asia and Europe (Gan et al. 2020). 
Ramosetron, also not approved in the USA, was found to be effective at a 0.3 mg IV dose. 
Palonosetron, introduced to the market in 2003, is a longer-acting, second generation 
serotonin antagonist with plasma half-life of 40 h (Horn et al. 2014, Rojas et al. 2014). 
Palonosetron 0.075 mg was shown to be more effective than the aforementioned 5-HT3 
antagonists with an efficacy that is comparable to aprepitant 40 mg PO (Gan et al. 2020). 
1.4.4 Antihistamines 
Even though H1 receptor antagonists such as dimenhydrinate have been used as antiemetics 
for many years, this class of agents is not well studied with the optimal dosing, time of 
administration and safety profile still remaining unclear (Kranke et al. 2002). Also data on 
promethazine for PONV prevention is very limited, with guidelines recommending a 6.25 mg 
dose. Notably, promethazine also carries a black-box warning for its risk of serious tissue 
damage when administered incorrectly and the FDA recommends a deep intramuscular 
injection as the preferred route of administration (Gan et al.2020). 
1.4.5 Neurokinin-1 receptor antagonists 
NK-1 receptor antagonists, a relatively new antiemetic class, act mostly in the NTS and the 





Aprepitant, available both in oral as well as parenteral (fosaprepitant) form, was shown to 
reduce emesis rather than nausea. Both aprepitant 40 mg IV and fosaprepitant 150 mg IV are 
more efficacious against PONV than ondansetron (Gan et al. 2020). Several other NK-1 
receptor antagonists, developed for controlling PONV, such as casopitant and rolapitant have 
not yet been approved for this indication (Liu et al.2015, Gan et al. 2020). 
1.4.6 Anticholinergics 
Scopolamine acts as a nonselective post-ganglionic muscarinic receptor antagonist and 
directly inhibits the transmission of cholinergic impulses in the vestibular nuclei (Horn et al. 
2014). Transdermal scopolamine patch was shown to be effective in PONV prevention up to 
24 hours after surgery with mild side effects including visual disturbances, dizziness and dry 
mouth (Apfel et al. 2010, Gan et al. 2020). Due to the late onset of effect, current guidelines 
recommend applying the patch the night before surgery or 2-4 hours before (Gan et al. 2020). 
1.4.7 Dopamine antagonists 
1.4.7.1 Overview 
Dopamin D2 and D3 receptors play an important role in nausea and vomiting, most probably 
by inhibiting the adenylate cyclase, with a consequent increase of cAMP in neurons located in 
the area postrema and the nucleus tractus solitarii. Competitive antagonism of these receptors 
is responsible for antiemetic properties of drug classes, such as phenotiazines (promethazine, 
chlorpromazine, perphenazine), benzamides (metoclopramide) and butyrophenones 
(droperidol and haloperidol) (Horn et al. 2014, Gan 2007). 
1.4.7.2 Phenotiazines 
Chlorpromazine and promethazine have been used in the past to treat PONV, however 
frequent adverse events including sedation and lethargy as well as lack of much evidence of 
their effect have limited their use (Gan 2007, Gan et al. 2014). Perphenazine at 5 mg dose has 
been shown to be effective in PONV prevention without the typical side effects of older 





Metoclopramide acts on D2, H1 and 5-HT3 receptors and shows additional prokinetic 
properties in the gastrointestinal tract through D2 antagonism and 5-HT4 agonism (Horn et al. 
2014). Even though metoclopramide has been widely used for many years, it’s clinical efficacy 
at preventing PONV is not certain (Gan et al. 2020). A 10 mg iv prophylactic dose was shown 
to be effective at preventing PONV and is recommended in current guidelines (De Oliveira Jr 
et al. 2012, Gat at al. 2020). A multicenter trial of 10, 25 and 50 mg metoclopramide in 
combination with 8 mg dexamethasone found that only 25 mg and 50 mg doses, administered 
30-60 min before the end of the operation, significantly reduced the incidence of PONV. 
However, the incidence of adverse events, such as tachycardia, hypotension and extrapyramidal 
disorders increased with increase in the drug’s dose. Therefore, a combination therapy with 
metoclopramide is not recommended (Wallenborn et al. 2006, Gan et al.2020). 
1.4.7.4 Haloperidol 
Haloperidol, a potent D2 antagonist, frequently used for the treatment of psychosis and 
agitation, has been shown to be effective at low doses (0.5-2 mg IM/IV) for the management 
of PONV. In this dosage, typical adverse effects, such as extrapyramidal symptoms or sedation 
were rare and no cardiac arrhythmias were reported (Buettner et al. 2004, Gan et al. 2020). 
Haloperidol carries a QTc prolongation risk in its label and its intravenous use as well as its use 
as an antiemetic is not FDA-approved (Gan et al. 2014, Gan et al. 2020). 
1.4.7.5 Droperidol 
The Dopamine D2-antagonist droperidol was a commonly used and cost-effective 
antiemetic up until 2001, when it received a black-box warning from the US Food and Drug 
Administration (FDA). Black-box warning highlights severe and life-threatening adverse 
reactions and consequently, provides advice about precautions and drug use restrictions in order 
to prevent serious adverse events (FDA. Guidance for Industry 2011). The warning on 
droperidol was based on cases of QTc interval prolongation (values ≥390 ms in men and ≥460 
ms in women) resulting in severe cardiac arrhythmias, such as torsade de pointes when used in 
doses >25 mg (Gan et al. 2020, McKeage et al. 2006, Rautaharju et al. 2009). Even though at 
low doses (0.625 to 1.25 mg IV) it has been shown to be safe and effective at preventing PONV, 




and Gan 2008). Consequently, research on alternative agents blocking the dopamine receptor 




Amisulpride (Solian ®), a substituted benzamide derivate has been on the market for over 
thirty years. The drug was first introduced in France and found its therapeutic use in the 
treatment of both positive and negative symptoms of schizophrenia in over 50 countries 
worldwide. Additionally, in Italy, it is also used for the treatment of dysthymia (Coulouvrat and 
Dondey-Nouvel 1999, Pani and Gessa 2002, Solian Product Information 2006). The 
recommended daily oral doses range from 50-800 mg/day and in individual cases can be 
increased up to 1200 mg/day (Solian Product Information 2006). 
1.4.7.6.2 Pharmacodynamics 
Amisulpride shows high selectivity for dopamine D2 (Ki = 2.8 nM), D3 (Ki = 3.2 nM) as 
well as 5-HT7a serotonin receptors with low affinity to other serotonin and dopamine receptor 
subtypes as well as histamine, adrenergic and cholinergic receptors. Low doses preferentially 
inhibit presynaptic dopamine receptors, enhancing dopamine transmission, while high doses 
block postsynaptic dopamine receptors, inhibiting the dopaminergic activity in the limbic 
system (Abbas et al. 2009, Schoemaker et al.1997). 
1.4.7.6.3 Pharmacokinetics and metabolism 
After oral route of administration amisulpride undergoes rapid biphasic absorption with 
first plasma peak concentration at 1h (Cmax = 42.3 ± 3.3 ng/ml) with subsequent one at 3 to 4 
hours (Cmax = 55.7 ± 3.7 ng/ml). Amisulpride shows extensive volume of distribution of 5,8 
l/kg, minimal hepatic metabolism and is primarily excreted in an unchanged form via the renal 
(22–25% after oral, 50% after IV administration) and faecal route (Fox et al. 2019, Rosenzweig 
et al. 2002). The terminal plasma elimination half-life (t½) is about 7–8 hours after intravenous 
and 12 hours after oral administration. Renal clearance (17–20 l/h, 330 ml/min) is decreased in 
patients with renal failure, therefore, in these patients the dose should be adjusted based on the 




amisulpride’s safe pharmacokinetic profile in the geriatric population (Solian Product 
Information 2006, Curran and Perry 2001). Minimal metabolism, low rate of plasma protein 
binding (17%) and no inhibition of the cytochrome CYP 450 isoenzymes contribute to 
amisulpride’s low risk for drug interactions (Gillet et al. 2000). 
 Aim of the study 
In 2010, a repurposed formula of amisulpride for intravenous injection was patented and 
since then various clinical trials were started to study its antiemetic potential in the management 
of PONV (Smyla et al. 2020). 
The purpose of this meta-analysis was to evaluate the efficacy and safety of intravenous 
amisulpride on both prevention and treatment of PONV from the clinical data available so far.
Materials and Methods 
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2. Materials and Methods 
 Clinical Studies Investigator 
From February 2016 until September 2016, I was a clinical investigator responsible for 
patient recruitment in two multicenter Phase III Studies, which looked at the effects of 
intravenous amisulpride on treatment of established PONV, later published by Candiotti et al. 
2019 and Habib et al. 2019. Both trials were conducted in accordance with the specifications 
of drug regulatory agencies to gain approval for a new drug. 
 Search strategy and study selection 
A systematic review (meta-analysis) was conducted according to the 2009 PRISMA 
guidelines. Two independent investigators searched MEDLINE (PubMed), ClinicalTrials.gov 
and Cochrane Controlled Register of Trials (CENTRAL) databases for randomized, controlled 
trials on intravenous amisulpride. No language or publication year restrictions were applied. 
Studies wherein the intervention groups receiving intravenous amisulpride for prophylaxis or 
treatment of PONV when compared to placebo or another antiemetic were included in the meta-
analysis. Keywords used in the search included “sultopride", "amisulpride", "postoperative 
nausea and vomiting", “ponv”, "nausea” and "vomiting". Exclusion criteria included non-
randomised trials, animal studies or review articles (Smyla et al.2019). 
 Data extraction 
Two independent investigators (Natalia Smyla and Prof. Leopold Eberhart) selected 
studies, extracted data as well as assessed the risk of bias. A modified Cochrane data collection 
form was used for data extraction. For duplicate removal and reference management Mendeley 
Version 1.19.2 was used. Disagreements were resolved by reaching a consensus with a third 
investigator (Dr. Stefanie Weibel and/or Prof. Peter Kranke). The risk of bias was assessed 
using the Cochrane Collaboration’s tool (Smyla et al. 2019). 
Materials and Methods 
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 Primary and secondary endpoints 
The primary endpoint of the study was the incidence of PONV (any episode of 
retching/vomiting or use of rescue medication) 24-hours postoperatively or 24-hours after IV 
amisulpride administration. Rescue medication use 24 hours after operation or study drug 
administration and the incidence of the most frequent treatment-emergent adverse events 
(TEAEs) were secondary endpoints of the study (Smyla et al. 2019). 
 Statistical analysis and risk of bias assessment 
 A random-effects model meta-analysis was carried out in ReviewManager (RevMan) 
[Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014. Results were calculated using the Mantel-Haenszel Method and presented 
as relative risk (RR) with 95% confidence interval (CI). The χ-square test and I² statistic were 
used to measure heterogeneity. For all outcomes, differences were considered significant at P 
values < 0.05. A subgroup analysis was carried out for different doses of IV amisulpride. Forest 
plots were created to illustrate the results. Risk of bias was assessed using the Cochrane risk-





 Study Selection 
The database search performed in February 2019 revealed altogether fourteen publications. 
Among these, seven were removed as they constituted duplicates and two studies were excluded 
after screening their titles and abstracts. Finally, five randomised, placebo-controlled studies 
(n= 3313) were assessed as eligible and included in the meta-analysis (Smyla et al. 2019) 
(Figure 1). 
 Study characteristics 
The five analysed studies were issued between 2013 and 2019 (Kranke et al. 2013, Gan et 
al. 2017, Kranke et al. 2018, Habib et al. 2019, Candiotti et al.2019). The Gan et al. study 
Figure 1. Flow chart of the literature search and study 




included two identical trials conducted in the USA and Europe and therefore, the pooled results 
of those trials were used for the meta-analysis.  
Three trials investigated amisulpride for the prophylaxis of postoperative nausea and 
vomiting; two of these tested amisulpride as monoprophylaxis, whereas one of the trials added 
one antiemetic with amisulpride or placebo. 
The remaining two studies analysed amisulpride versus placebo in the treatment of PONV 
(Candiotti et al. - in patients not receiving any prophylaxis and Habib et al. in patients who have 
been administered up to three prophylactic antiemetics). 
The characteristics of the five included studies such as number of patients, the percentage 
of female participants, baseline risk of PONV, anaesthesia type and prior PONV prophylaxis 




Table 2. Characteristics of included studies (Adapted and modified from Smyla et al. 2019). 
  








10 mg Placebo 
Amisulpride 
5 mg Placebo 
Amisulpride 






20 mg Placebo 
Number od subjects (n) 237 230 235 191 188 181 572 575 315 311 58 50 53 54 












75% 78% 91% 96% 92% 87% 
History of PONV 123 (51.9%) 110 (47.8%) 121 
(51.5%) 
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33 
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(62.4%) 69% overall abdominal surgery, 24% breast or 
axillary surgery; laparoscopic technique was 
used in 25% of patients 




















 Primary Endpoints 
Three studies tested intravenous amisulpride (Kranke et al. 2013 1, 5 and 20 mg doses; Gan 
etl al. and Kranke et al 2018 5 mg) in the prevention of postoperative nausea and vomiting 24-
hours after surgery. PONV was defined as any retching/vomiting (emesis) or the use of rescue 
medication. The secondary endpoint included the incidence of nausea.  
Two studies examined 5 and 10 mg amisulpride doses for the treatment of established 
PONV (episode of retching/vomiting or nausea up to 24 hours postoperatively, for which 
patients requested antiemetic medication). 
Both trials then evaluated the incidence of PONV, defined as an emetic episode or the use 
of rescue medication from 30 minutes to 24 hours postoperatively. 
Figure 2 shows the efficacy of 1, 5 and 20 mg intravenous amisulpride on PONV 
prophylaxis 24 hours after surgery. The pooled effect estimate of all trials revealed a significant 
decrease in the incidence of PONV (RR = 0.78; 95% CI, 0.72–0.85, p < 0.00001) in patients 
receiving amisulpride as compared to placebo. Subgroup analysis according to the administered 
dose showed that only doses of 1 and 5 mg and not 20 mg amisulpride significantly reduced 
the risk of PONV.  
 
Figure 2. Forest plot showing the effect of intravenous amisulpride for PONV prophylaxis 24 hours 




Figure 3 shows the effect of 5 and 10 mg intravenous amisulpride dose 24 hours after 
administration. Both 5 mg (RR = 0.9; 95% CI, 0.83–0.98; p = 0.02) and 10 mg amisulpride 
doses (RR = 0.85; 95% CI, 0.77–0.93; p = 0.0004) significantly reduced the incidence of PONV 
with overall RR of 0.87 (95% CI; 0.82–0.93, p < 0.0001). 
 
Figure 3. Forest plot showing the effect of intravenous amisulpride for PONV treatment 24 hours 
after administration. This figure was adapted and modified from (Smyla el al. 2019). 
 Secondary Endpoints 
3.4.1 Use of rescue medication 
Figure 4 shows the rescue medication use 24 hours after surgery or study drug 
administration. Amisulpride significantly decreased the use of rescue medication as compared 





Figure 4. Forest plot showing the rescue medication use 24 hours postoperatively or after study drug 
administration. This figure was adapted and modified from (Smyla el al. 2019). 
3.4.2 Treatment Emergent Adverse Events (TEAE) 
The incidence of reported TEAE was significantly lower in the amisulpride group as 





Figure 5. Forest plot showing the incidence of treatment emergent adverse events occurring 24 hours 
after surgery or study drug administration. 
3.4.3 Severe Adverse Events (SAE) 
The meta-analysis showed no significant difference in the incidence of SAE between 




3.4.4 Life-threatening Adverse Events 
There was no significant difference in the incidence of life-threatening adverse events 
between amisulpride and placebo groups (RR= 0.41; 95% CI, 0.13–1.28, p=0.13) (Figure 7). 
 
Figure 6. Forest plot showing the incidence of severe adverse events occurring 24 hours after 





The incidence of insomnia/sleep disorder, reported in one study (Kranke et al. 2013) was 
found to be significantly higher in the amisulpride group than in the placebo (RR= 2.13; 95% 
CI, 0.99–4.57, p=0.05) (Figure 8). 
 
Figure 7. Forest plot showing the incidence of life-threatening adverse events occurring 24 hours 





Figure 8. Forest plot showing the incidence of insomnia occurring 24 hours after surgery. 
3.4.6 Blood prolactin increased 
There was a larger increase in blood prolactin levels, as observed in the Gan et al. study, in 
the amisulpride group as compared to placebo (RR= 8.97; 95% CI, 2.75–29.30, p=0.0003) 
(Figure 9). 
 
Figure 9. Forest plot showing the incidence of hyperprolactinaemia occurring 24 hours after study 
drug administration. 
3.4.7 Pyrexia 
Pyrexia was reported in just one study with no significant difference between the 





Figure 10. Forest plot showing the incidence of pyrexia occurring 24 hours after study drug 
administration. 
3.4.8 Abdominal distension 
Abdominal distension was an endpoint in one study with no significant difference between 
the study groups (RR= 1.63; 95% CI, 0.78–3.40, p=0.19) (Figure 11). 
 
Figure 11. Forest plot showing the incidence of abdominal distension occurring 24 hours after study 
drug administration. 
3.4.9 Nausea and Vomiting 
“The meta-analysis showed no significant difference in the incidence of nausea (RR = 0.93; 
95% CI, 0.77–1.13, p = 0.47) and vomiting (RR = 0.860; 95% CI, 0.52-1.24, p = 0.32), 
excluding events occurring in the first 24 hours after the end of surgery or the study drug 
administration, reported as a TEAE in four and two studies, respectively.” (Smyla et al.2019) 





Figure 12. Forest plot showing the incidence of nausea excluding events occurring 24 hours after 
surgery or study drug administration. 
 
Figure 13. Forest plot showing the incidence of vomiting excluding events occuring 24 hours after 
surgery or study drug administration. 
3.4.10 Hypertension 
Hypertension was detected as an adverse event in one study with no significant differences 





Figure 14. Forest plot showing the incidence of hypertension occurring 24 hours after study drug 
administration. 
3.4.11 Flatulence 
Four studies observed flatulence as an adverse effect. No significant difference was found 






Figure 15. Forest plot showing the incidence of flatulence 24 hours after surgery or study drug 
administration. 
3.4.12 Constipation 
All 5 studies evaluated the rate of constipation. The pooled analysis showed no significant 
difference between amisulpride and placebo group (RR= 0.91; 95% CI, 0.71–1.20, p=0.43) 
(Figure 16). 
 
Figure 16. Forest plot showing the incidence of constipation 24 hours after surgery or study drug 
administration. 
3.4.13 Chills 
The meta-analysis showed no significant difference in the incidence of chills, as reported 





Figure 17. Forest plot showing the incidence of constipation 24 hours after surgery. 
3.4.14 Pruritus 
A total of two studies reported pruritus as an adverse event. The meta-analysis showed no 
significant difference between amisulpride and placebo group (RR= 0.86; 95% CI, 0.55–1.35, 
p=0.89) (Figure 18). 
 
Figure 18. Forest plot showing the incidence of pruritus 24 hours after surgery or study drug 
administration. 
3.4.15 Anaemia 
Two studies reported anaemia as a TEAE. The pooled analysis revealed no significant 






Figure 19. Forest plot showing the incidence of anaemia 24 hours after surgery. 
3.4.16 Hyperglycemia 
The occurrence of hyperglycemia, as reported in one study, did not differ between 
amisulpride and placebo group (RR= 0.87; 95% CI, 0.56–1.35, p=0.52) (Figure 20). 
 
Figure 20. Forest plot showing the incidence of hyperglycemia 24 hours after surgery. 
3.4.17 Leukocytosis 
Only the Gan et al. study reported leukocytosis as an adverse event, which did not differ 
significantly between amisulpride and placebo group (RR= 1.13; 95% CI, 0.66–1.94, p=0.66) 
(Figure 21). 
 





The meta-analysis showed no difference between the amisulpride and placebo groups in 
the incidence of dizziness, as reported in one study. (RR= 0.76; 95% CI, 0.21–2.73, p=0.48) 
(Figure 22). 
 
Figure 22. Forest plot showing the incidence of dizziness 24 hours after surgery. 
3.4.19 Hypotension 
Three of the included trials reported hypotension as an adverse event, with no difference in 






Figure 23. Forest plot showing the incidence of hypotension 24 hours after surgery. 
3.4.20 Pain 
Procedural pain was reported in 3 studies (Kranke et al. 2013, Gan et al. 2017, Kranke et 
al. 2018), while 2 studies reported infusion site pain (Candiotti et al. 2018; Habib et al. 2019). 
The pooled analysis of the available data showed no significant difference between amisulpride 





Figure 24. Forest plot showing the incidence of pain 24 hours after surgery or study drug 
administration. 
3.4.21 Hypoproteinemia 
The incidence of hypoproteinemia, reported in one study, did not vary between the 
amisulpride and placebo group (RR= 1.04; 95% CI, 0.62–1.74, p=0.90) (Figure 25). 
 
Figure 25. Forest plot showing the incidence of hypoproteinemia 24 hours after surgery. 
3.4.22 Headache 
Four studies evaluated the rate of headache. The pooled analysis showed no significant 






Figure 26. Forest plot showing the incidence of headache 24 hours after surgery or study drug 
administration. 
3.4.23 Hypocalcaemia 
Hypocalcaemia was reported as a TEAE in one study. Its incidence was not statistically 
significant between amisulpride and placebo group (RR= 1.00; 95% CI, 0.61–1.62, p=0.99) 
(Figure 27). 
 
Figure 27. Forest plot showing the incidence ofhypocalcamie 24 hours after surgery. 
3.4.24 Summary of safety outcomes for intravenous amisulpride 
Table 3 summarizes the pooled risk ratios with 95% confidence intervals for each safety 




 Risk of bias assessment 
The risk of bias in all trials included in the meta-analysis was evaluated as low by two 
independent investigators. All trials were sponsored by Acacia Pharma Ltd, Cambridge, UK. A 






Table 3. Meta-analysis of overall adverse events; N, number of patients; TEAE, treatment-emergent 
adverse event; SAE, severe adverse event; AE, adverse event. (Adapted from Smyla et al. 2019). 













any TEAE 5 3313 0.90 [0.84, 0.96] 0.0008 
Insomnia 1 215 2.13 [0.99, 4.57] 0.05 
any life-
threatening AE 









Pyrexia 1 215 4.72 [0.55, 40.87] 0.16 
Abdominal 
distension 
1 689 1.63 [0.78, 3.40] 0.19 
Vomiting* 2 1849 0.80 [0.52, 1.24] 0.32 
Hypertension 1 215 1.99 [0.49, 8.06] 0.33 
Flatulence 4 2166 0.89 [0.69, 1.14] 0.35 
Constipation 5 3313 0.91 [0.71, 1.16] 0.43 
Nausea* 4 3098 0.93 [0.77, 1.13] 0.47 
Chills 1 1147 1.26 [0.66, 2.40] 0.49 
Pruritus 2 1391 0.86 [0.55, 1.35] 0.52 
Anaemia 2 904 1.19 [0.7, 2.04] 0.52 
Hyperglycemia 1 689 0.87 [0.56, 1.35] 0.52 
Leukocytosis 1 689 1.13 [0.66, 1.94] 0.66 
Dizziness 1 215 0.76 [0.21, 2.73] 0.68 
any SAE 5 3313 0.95 [0.65, 1.39] 0.79 
Hypotension 3 2051 1.05 [0.69, 1.59] 0.82 
Pain 5 3313 1.01 [0.90, 1.13] 0.89 
Hypoproteinemia 1 689 1.04 [0.62, 1.74] 0.9 
Headache 3 1606 1.00 [0.50, 1.97] 0.99 
Hypocalcemia 1 689 1.00 [0.61, 1.62] 0.99 





This meta-analysis shows that prophylactic use of intravenous amisulpride effectively 
reduces the risk of PONV and rescue medication use in the 24-hour postoperative period as 
well as up to 24 hours after its therapeutic use with an overall lower incidence of adverse events 
as compared to the placebo group. 
The only adverse events which occurred more frequently in patients receiving amisulpride 
were insomnia and elevated serum prolactin levels, however, their clinical relevance is 
questionable. Insomnia, which was reported in the study of Kranke et al., first occurred more 
than 48 h after amisulpride administration, which is significantly more than 5-fold the half-life 
of the intravenous dose (Kranke et al. 2013). 
 Hyperprolactinaemia is a common side effect of dopamine receptor antagonists, caused by 
the D2 antagonism on the anterior pituitary lactotroph cells with subsequent loss of the 
inhibition of prolactin secretion (Kim et al. 2012). The mean prolactin increase in the Gan et al. 
study was small and did not exceed the norm for non-pregnant women (Gan et al. 2017). The 
effect of a single 10 mg IV amisulpride dose on prolactin levels appears to be short-lived, with 
a 10-fold increase at 1 hour, with prolactin levels returning to the norm by 12 hours (Fox et al. 
2019). 
Common side effects associated with the use of dopamine antagonists include 
extrapyramidal symptoms, such as tremor, akathisia, bradykinesia, Parkinson-like rigidity, 
acute dystonia and tardive dyskinesia, yet none of such symptoms were reported in the studies 
on the IV amisulpride for PONV, which is consistent with a recent meta-analysis involving data 
from psychiatric population studies (Huhn et al. 2019). 
The main concern associated with the use of dopamine antagonists is its cardiovascular 
toxicity. Amisulpride was shown to be cardiovascular-safe in the psychiatric population, where 
doses up to 1200 mg per day are administered daily (Coulouvrat and Dondey-Nouvel 1999). 
However, an overdose (4-80 g) can lead to QTc prolongation and the development of severe 
cardiac arrhythmias, such as torsade de pointes (Isbister et al. 2010). Low doses of 5 mg IV 
tested for PONV do not lead to the QTc interval prolongation, while higher, supratherapeutic 
doses (40 mg IV) prolong the QTc interval by 23.4 ms from baseline, never exceeding absolute 
QTcF value of > 500 ms. Therefore, the QTc interval prolongation seems to be dose-dependent 
(Täubel et al. 2017). 
Current therapy guidelines for PONV recommend multimodal prevention approach, 




results (Gan et al. 2020). Due to safety concerns raised by the FDA in 2001, when the black-
box warning was issued on droperidol, which was once a first-line therapy agent for PONV, its 
use has significantly declined, leading to the search for alternative antiemetics targeting the 
dopamine receptor (Habib and Gan 2008). The most obvious candidate, haloperidol, frequently 
used for the treatment of psychosis and agitation, was also labeled with a black-box warning in 
2007 due to the risk of QTc prolongation (Gan et al. 2014). Another potential candidate, 
metoclopramide, was proven to be effective only at higher doses, which are associated with 
higher incidence of adverse events including extrapyramidal symptoms, hypotension and 
tachycardia. Therefore, it is also not recommended as a first-line therapy (Wallenborn et al. 
2006). Another representative of phenothiazine group, perphenazine was proven effective at 5 
mg doses for preventing PONV, however data on the timing, route of application and the most 
effective dose is very limited (Schnabel et al. 2010). Amisulpride, with its favourable safety 
profile and low risk of drug interactions emerges as the most interesting potential substitute to 
droperidol, particularly in patients with a high cardiovascular risk profile.  
Even though the black-box warning for droperidol remains controversial, with studies 
proving that low doses ( < 1 mg or < 15 µg/kg) are effective and cardiocascular-safe, many 
clinicians stopped using droperidol after 2001. This was not only for safety reasons, but also 
due to its lack of its availability after voluntary withdrawal from the market by the 
manufacturer, which in turn led to decrease in its use, mostly in the United States. However, in 
the majority of European countries, droperidol was still administered as an antiemetic or its 
withdrawal was only temporary like in the United Kingdom or in Spain (Schaub et al. 2012). 
A possible limitation of the trials included in the meta-analysis is that most of the 
participants were female patients (87,5%), therefore the results might not represent the whole 
surgical population; nonetheless, women are much more prone to suffer from PONV than men 
(Smyla et al. 2019). 
Another limitation is that all recruited patients were adults, thus the efficacy and safety of 
intravenous amisulpride in children remains unknown. However, dopamine antagonists are not 
recommended as a first line PONV therapy due to the generally increased susceptibility of 
paediatric population to this pharmacological class (Smyla et al.2019). 
The amount of studies available so far on intravenous amisulpride for PONV prophylaxis 
and treatment is very limited. The pooled effect estimates with 95% confidence interval were 
statistically significant, but reach the areas of clinical irrelevance (RR 0.8-1.25); therefore more 




limitation. Furthermore, studies comparing amisulpride to well-known antiemetics such as 
dexamethasone or ondansetron are necessary to evaluate its clinical relevance. 
In February 2020 Barhemsys, the repurposed intravenous formula of amisulpride hasd 
gained its FDA approval for both prevention and therapy of PONV. The recently published 
Fourth Consensus Guidelines for The Management of Postoperative Nausea and Vomiting 
recommend a 5 mg dose at induction of anaesthesia as a part of a multimodal antiemetic 
approach (Gan et al. 2020). Amisulpride’s success on the market will mostly depend on its cost-
effectiveness. Nowadays, the costs of generic formulations of droperidol are low, while the 
brand-new intravenous formula of amisulpride will lack such cost efficiency (Smyla et al.2020). 
In conclusion, intravenous amisulpride emerges as an effective and safe antiemetic for both 
prevention and treatment of postoperative nausea and vomiting. It can be used in mono- and 
combination therapy with other antiemetics as a part of a multimodal management of PONV. 
It’s favourable safety profile, no relevant QTc interval prolongation, low risk of drug 
interactions make it the most interesting representative of the dopamine antagonist group of 
antiemetics. Further studies on intravenous amisulpride with active controls are needed to 
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Background: Despite the advances in anesthesiology, postoperative nausea and vomiting 
(PONV) with its complex aetiology still remains a common postoperative complication for 
many patients. Dopamine D2-antagonist droperidol was a frequently used cost-effective 
antiemetic up until 2001, when the FDA issued a black-box warning in its label. Since then, 
more focus has been put on the research on alternative agents blocking the dopamine receptor. 
In 2010, a repurposed formula of intravenous amisulpride, an atypical antipsychotic, which 
has been on the market for over thirty years, was patented and since then various clinical trials 
were started to study its antiemetic potential in the management of PONV. 
Objectives: The purpose of this meta-analysis was to evaluate the efficacy and safety of 
intravenous amisulpride on both prevention and treatment of PONV from the clinical data 
available so far. 
Methods: A systematic review (meta-analysis) was conducted according to the 2009 
PRISMA guidelines. Two independent investigators searched MEDLINE (PubMed), 
ClinicalTrials.gov and Cochrane Controlled Register of Trials (CENTRAL) databases for 
randomized, controlled trials on intravenous amisulpride without language or publication year 
restrictions. Studies with intervention group receiving intravenous amisulpride for prophylaxis 
or treatment of PONV as compared to placebo or another antiemetic were included in the meta-
analysis. The primary endpoint of the study was the incidence of PONV (any episode of 
retching/vomiting or use of rescue medication) 24-hours postoperatively or 24-hours after IV 
amisulpride administration. Rescue medication use 24 hours after operation or study drug 
administration and the incidence of the most frequent treatment-emergent adverse events 
(TEAEs) were secondary endpoints of the study. Results were calculated using the Mantel-
Haenszel Method and presented as relative risk (RR) with 95% confidence interval (CI). 
Results: Data of five eligible trials (n=3313) were included in the final meta-analysis. 
Three of those trials investigated amisulpride for the prophylaxis of postoperative nausea and 
vomiting; while two studies analysed amisulpride versus placebo as treatment of PONV. The 
pooled effect estimate of all trials revealed a significant decrease in the incidence of PONV 
(RR = 0.78; 95% CI, 0.72–0.85, p < 0.00001) in patients receiving amisulpride as compared to 
placebo. Subgroup analysis according to the administered dose showed that only 1 and 5 mg 
and not 20 mg amisulpride doses significantly reduced the risk of PONV. Both 5 mg (RR = 0.9; 




= 0.0004) significantly reduced the incidence of PONV up to 24 hours after treatment with 
overall RR of 0.87 (95% CI; 0.82–0.93, p < 0.0001). Safety results showed a significant 
decrease in adverse events (AEs) in the amisulpride group as compared to placebo (RR = 0.9; 
95% CI, 0.84-0.96; P = 0.008). Out of all the reported AEs, only increased blood prolactin level 
(RR = 8.97; 95% CI, 2.75-29.30; P = 0.0003) and insomnia (RR = 2.13; 95% CI, 0.99-4.57; P 
= 0.05), both reported in 1 study, occurred significantly more frequently in the amisulpride than 
the placebo group. 
Conclusions: This meta-analysis shows that prophylactic use of intravenous amisulpride 
effectively reduces the risk of PONV and rescue medication use in the 24-hour postoperative 
period as well as up to 24 hours after its therapeutic use with overall lower incidence of adverse 
events as compared to placebo. It can be used in mono- and combination therapy with other 
antiemetics as a part of multimodal management of PONV. It’s favourable safety profile, no 
relevant QTc interval prolongation, low risk of drug interactions make it the most interesting 
potential droperidol substitute. Further studies on intravenous amisulpride with active controls 






Hintergrund: Trotz der Fortschritte in der Anästhesiologie, bleibt postoperative Übelkeit 
und Erbrechen (PONV) mit ihrer komplexen Ätiologie bleibt für viele Patienten immer noch 
eine häufige postoperative Komplikation. Dopamin-D2-Antagonist Droperidol war bis 2001 
ein häufig verwendetes und kostengünstiges Antiemetikum, bis die FDA eine Black-Box-
Warnung herausgab. Seitdem wurde mehr Wert auf die Erforschung alternativer Wirkstoffe 
gelegt, die den Dopaminrezeptor blockieren. 
Im Jahr 2010 wurde eine neue, intravenöse Formel von Amisulprid, einen atypischen 
Antipsychotikum, das seit über 30 Jahren auf dem Markt verfügbar ist, patentiert.  
Seitdem wurden diverse klinische Studien gestartet, um dessen antiemetisches Potenzial 
bei der Behandlung von PONV zu untersuchen. 
Ziele der Studie: Ziel dieser Metaanalyse war es, die Wirksamkeit und Verträglichkeit von 
intravenösem Amisulprid sowohl bei der Prävention als auch bei der Behandlung von PONV 
anhand der bisher verfügbaren klinischen Daten zu bewerten. 
Methoden: Die Metaanalyse wurde gemäß den PRISMA-Richtlinien von 2009 
durchgeführt.  
Zwei unabhängige Prüfer durchsuchten die Datenbanken MEDLINE (PubMed), 
ClinicalTrials.gov und Cochrane Controlled Register of Trials (CENTRAL) nach 
randomisierten, kontrollierten Studien zu intravenösem Amisulprid ohne Einschränkungen 
hinsichtlich der Sprache oder dem Erscheinungsjahr. Studien mit Interventionsgruppen, die 
intravenöses Amisulprid zur Prophylaxe oder Behandlung von PONV im Vergleich zu Placebo 
oder einem anderen Antiemetikum erhielten, wurden in die Metaanalyse einbezogen. Der 
primäre Endpunkt der Studie war die Inzidenz von PONV (jede Episode von Würgen / 
Erbrechen oder die Gabe von antiemetischer Rescue-Medikation) 24 Stunden postoperativ oder 
24 Stunden nach intravenöser Verabreichung von Amisulprid. Antiemetische Rescue-
Behandlung 24 Stunden nach der Operation oder der Verabreichung des Studienmedikaments 
sowie die Inzidenz der häufigsten behandlungsbedingten unerwünschten Ereignissen waren 
sekundäre Endpunkte der Studie. Die Ergebnisse wurden unter Verwendung der Mantel-
Haenszel-Methode berechnet und als relatives Risiko (RR) mit einem Konfidenzintervall von 
95% (CI) dargestellt. 
Ergebnisse: Daten von fünf geeigneten Studien (n = 3313) wurden in die endgültige 




PONV; in den zwei anderen Studien wurde Amisulprid im Vergleich zu Placebo als 
Behandlung von PONV getestet. Die gepoolte Effektschätzung aller Studien ergab eine 
signifikante Abnahme der PONV-Inzidenz (RR = 0,78; 95% CI, 0,72–0,85, p <0,00001) bei 
Patienten, die Amisulprid erhielten, im Vergleich zu Placebo. Eine Untergruppenanalyse 
gemäß der verabreichten Dosis zeigte, dass nur 1 und 5 mg, nicht aber 20 mg Amisulprid-Dosen 
das PONV-Risiko signifikant verringerten. Sowohl 5 mg (RR = 0,9; 95% CI, 0,83–0,98; p = 
0,02) als auch 10 mg Amisulprid-Dosen (RR = 0,85; 95% CI, 0,77–0,93; p = 0,0004) 
reduzierten die Inzidenz von PONV signifikant bis zu 24 Stunden nach der Behandlung mit 
einem Gesamt-RR von 0,87 (95% CI; 0,82–0,93, p <0,0001). Die Sicherheitsergebnisse zeigten 
eine signifikante Abnahme von unerwünschten Ereignissen in der Amisulpridgruppe im 
Vergleich zu Placebo (RR = 0,9; 95% CI, 0,84–0,96; P = 0,008). Von allen berichteten 
Nebenwirkungen traten in der Amisulpridegruppe im Vergleich zu Placebo nur ein erhöhter 
Prolaktinspiegel im Blut (RR = 8,97; 95% CI 2,75-29,30; P = 0,0003) und erhöhte 
Schlaflosigkeit (RR = 2,13; 95% CI 0,99-4,57; P = 0,05) signifikant häufiger auf. Beiden 
wurden in einer Studie berichtet. 
Schlussfolgerungen: Diese Metaanalyse zeigt, dass die prophylaktische Anwendung von 
intravenösem Amisulprid das Risiko von PONV- und antiemetischer Rescue-Medikation in der 
24-Stunden-Postoperationsperiode sowie bis zu 24 Stunden nach der therapeutischen 
Anwendung wirksam verringert, wobei die Häufigkeit unerwünschter Ereignisse im Vergleich 
zu Placebo insgesamt geringer ist. Amisulpride kann in der Mono- und Kombinationstherapie 
mit anderen Antiemetika als Teil des multimodalen Managements von PONV eingesetzt 
werden. Das vorteilhafte Verträglichkeitsprofil, keine relevante Verlängerung des QTc-
Intervalls und das geringe Risiko von Arzneimittelwechselwirkungen machen es zum 
interessantesten potenziellen Droperidolersatz. Weitere Studien zu intravenösem Amisulprid 
mit aktiven Kontrollen sind erforderlich, um seine Wirksamkeit mit etablierten Antiemetika 
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Summary
Background: Postoperative nausea and vomiting (PONV) is 
a distressing complication of surgery. Droperidol has been 
widely used as an antiemetic for several decades. As a result 
of the Food and Drug Administration’s “black box” warning 
on droperidol, research on alternative drugs acting on dopa-
mine receptors has been intensified. Amisulpride is an atypi-
cal antipsychotic drug first introduced in France in 1986 and 
since then approved for the treatment of acute and chronic 
schizophrenia in many countries. Recently, a new formula 
of an aqueous solution of amisulpride suitable for intrave-
nous injection was developed. Objectives: The aim of this 
review is to highlight the basic pharmacological profile and 
to report a meta-analysis on the safety and efficacy of 
intravenous amisulpride for the prevention and treatment of 
PONV. Methods: According to the 2009 PRISMA guidelines, 
a systematic search of MEDLINE via PubMed, ClinicalTrials.
gov and Cochrane Controlled Register of Trials (CENTRAL) 
for randomized, controlled trials, without restrictions, was 
conducted by two independent investigators (Dec 2013-
Feb 2019). Randomized, controlled trials, reporting the 
incidence of PONV in patients undergoing general anes-
thesia with an intervention group, receiving amisulpride 
either as prophylaxis or treatment compared to placebo 
or active interventions, were included in the meta-anal-
ysis. The primary endpoint was the incidence of PONV, 
defined as any episode of vomiting/retching or any use of 
antiemetic rescue medication 24 hours after operation or 
study drug administration. Secondary endpoints included 
the incidence of rescue antiemetic use within the 24-hour 
postoperative period or 24 hours after amisulpride admin-
istration, as well as the incidence of adverse events. Meta-
analysis was performed using a random-effects model 
and data are presented as RR (relative risk) with 95% con-
fidence interval (CI). Results: Data of 5 placebo-controlled 
studies including 3,313 patients were finally included 
in the meta-analysis. Three studies investigated the pre-
vention of PONV while 2 studies compared amisulpride to 
placebo in the treatment of PONV. Intravenously admin-
istered amisulpride during surgery decreased the risk of 
PONV compared to placebo (RR = 0.78; 95% CI, 0.72-0.85; 
P < 0.00001). Subgroup analysis according to dose of the inter-
vention suggested no relevant dose effect. However, the num-
ber of included studies was small. Treatment of PONV with 
5 and 10 mg amisulpride decreased the risk of PONV in the 
following 24 hours compared to placebo (RR 0.87; 95% CI, 
0.82-0.93; P < 0.0001). There was no difference between 5 and 
10 mg amisulpride detectable. There was a significantly lower 
risk of postoperative adverse events with amisulpride as com-
pared to placebo (RR = 0.9; 95% CI, 0.84-0.96; P = 0.008). There 
was no significant difference in the risk of severe adverse 
events (RR = 0.95, 95% CI, 0.65-1.39; P = 0.79). Conclusions: The 
meta-analysis demonstrates that intravenous amisulpride 
effectively reduced the risk of PONV in patients undergo-
ing general anesthesia within the first 24 hours postopera-
tively as well as within 24 hours after therapeutic use when 
administered as an antiemetic rescue medication. However, 
there are currently few studies investigating amisulpride 
as prophylaxis and treatment for PONV. The estimated 





A meta-analysis of amisulpride for PONV N. Smyla et al.
454 Drugs of the Future 2019, 44(6)
of clinical nonrelevance (RR > 0.8). Furthermore, a compar-
ison of amisulpride with the recommended dose of 5 mg 
against well-known active interventions for prevention of 
PONV, such as ondansetron or dexamethasone, are neces-
sary to put the presented results into context. Future trials 
may also investigate other patient populations, e.g., pedi-
atric patients.
Key words: Amisulpride – Postoperative nausea and 
vomiting – Dopamine D2/D3 receptor antagonist – Meta- 
analysis
Background
Postoperative nausea and vomiting (PONV) is a fre-
quent complication associated with general anesthesia. 
Nowadays, with modern anesthetics and new classes 
of antiemetic drugs, PONV still occurs in approximately 
20-30% of all patients undergoing surgery and in up to 80% 
of the patients with a high-risk profile (1, 2). Although often 
referred to as a big “little” problem (3), PONV may lead to 
dehydration and electrolyte imbalances, wound dehiscence 
and other severe complications, such as aspiration of the 
gastric contents, esophageal rupture, pneumothorax, sub-
cutaneous emphysema as well as loss of vision (4, 5). PONV 
is a leading cause of dissatisfaction with anesthesia. Not 
surprisingly, patients are willing to pay up to USD 100 for 
a completely effective therapy (6-8). Furthermore, it can be 
an economical issue due to a prolonged stay in the recovery 
room after surgery, additional antiemetic medication, extra 
nursing time, delays in discharge, and, finally, unplanned 
readmission in the outpatient setting (8-11).
Droperidol, a relatively selective D2 receptor antagonist, 
has been widely used as an antiemetic for several decades 
(12, 13). Doses ranging from 0.625 to 1.25 mg i.v. have been 
shown to be effective for PONV prophylaxis (2). However, in 
2001, the U.S. Food and Drug Administration (FDA) issued a 
“black box” warning based on cases of QTc prolongation and 
serious cardiac arrhythmias, such as torsades de pointes 
(TdP) (14, 15). The “black box” is used to highlight serious 
and life-threatening adverse events (AEs) and inform about 
precautions as well as implement restrictions so that the 
serious adverse reactions can be prevented (16). The FDA 
recommended that all patients should receive a 12-channel 
electrocardiogram before droperidol administration in 
order to assess if a prolonged QT interval (QTc interval of 
≥ 460 ms in women and ≥ 450 ms in men) is present, and 
in these cases droperidol use is considered contraindicated. 
Furthermore, a continuous electrocardiogram monitoring 
up to 2-3 hours after treatment should be performed in 
patients that received droperidol (17, 18). Since droperidol 
is usually administered at the end of surgery, additional 
monitoring creates additional workload. As a result of these 
concerns, research on alternative drugs acting on dopamine 
receptors has recently been intensified (2, 14, 15).
Amisulpride is an atypical antipsychotic drug first intro-
duced in France in 1986 under the name Solian and since 
then approved for the treatment of positive and negative 
symptoms of acute and chronic schizophrenia in many 
European countries as well as in Australia (19, 20). The 
recommended doses of oral amisulpride for patients with 
negative symptoms are 50-300 mg/day, 400-800 mg/day for 
patients with psychotic episodes, but in individual cases 
the dose can be increased up to 1200 mg/day (20).
Amisulpride is rapidly absorbed after oral administra-
tion and has a biphasic absorption profile. The first 
plasma peak concentration occurs after 1 h (Cmax = 42.3 ± 
3.3 ng/mL) followed by a second one between 3 and 4 h 
(Cmax = 55.7 ± 3.7 ng/mL). The absolute bioavailability of 
a 50-mg amisulpride tablet is about 50%. Amisulpride is 
rapidly and widely distributed to the body tissues with 
a volume of distribution of 5.8 L/kg (21, 22). The lack of 
inhibition of the cytochrome P450 and low plasma pro-
tein binding (17%) contribute to low propensity for drug 
interactions (21). Metabolism of amisulpride is minimal 
and the two main metabolites are inactive. Amisulpride is 
primarily excreted in an unchanged form in urine (22-25% 
after oral and almost 50% after intravenous administra-
tion) and in feces. The terminal plasma elimination half-
life (t½) is approximately 7-8 h after intravenous and 12 h 
after oral dose. Renal clearance ranges from 17 to 20 L/h 
(330 mL/min) (23, 24). Amisulpride has a safe pharmacoki-
netic profile in elderly patients, in which no dose modifica-
tion seems to be necessary (22). However, in patients with 
renal failure the doses might have to be adjusted, as ami-
sulpride’s peak plasma concentration increases linearly 
with the degree of renal impairment (25).
Amisulpride shows high affinity and selectivity for dopa-
mine D2 (Ki = 2.8 nM) and D3 (Ki = 3.2 nM) receptors, mainly 
those localized in the limbic system rather than in the 
striatum. At low doses, amisulpride blocks presynaptic dopa-
mine receptors, resulting in an increased dopamine trans-
mission, while at higher doses it blocks postsynaptic D2/D3 
receptors (26, 27). It has low affinity to adrenergic, musca-
rinic, histamine, serotonin (with the exception of 5-HT2B and 
5-HT7A) as well as dopamine D1, D4  and D5 receptors (23, 28).
Amisulpride tablets are practically insoluble in water (20). 
Since intravenous application is the preferred route for anti-
emetic administration in the perioperative setting, recently 
a new, patent-protected formula of aqueous citrate- 
buffered solution of amisulpride, suitable for intravenous 
injection, was developed for the treatment of nausea and 
vomiting (29).
This meta-analysis of amisulpride trials was conducted to 
evaluate the safety and efficacy associated with its use for 
prevention and treatment of PONV and provide clinicians 
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The heterogeneity of the results was measured using the 
χ-square and I² statistic. P values < 0.05 were considered 
statistically significant. A subgroup analysis was per-
formed for different doses of amisulpride. To illustrate the 
results, Forest plots were created. Cochrane risk-of-bias 
tool for randomized trials was used to assess the potential 
risk of bias in all included studies (32). The meta-analysis 
was carried out using ReviewManager (RevMan) [Computer 
program] Version 5.3. Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2014.
Results
Study selection
A total of 9 publications were identified, 2 of which were 
removed due to duplication. Two studies were excluded 
based on their title and available abstract. Data of 5 eligible, 
full-text randomized, placebo-controlled studies with 3,313 
patients were extracted and included in the final meta- 
analysis (Fig. 1).
Included studies’ characteristics
The 5 analyzed articles (33-37) were published between 
December 2013 and February 2019. One study con-
sisted of 2 identical trials conducted in Europe and the 
United States; thus, the pooled results were used for the 
meta-analysis (34).
A total of 3 studies investigated amisulpride for the pre-
vention of PONV; 2 of those studies used amisulpride as 
mono-prophylaxis, while 1 of the studies combined one 
additional antiemetic with amisulpride or placebo (see 
Table I). Another 2 studies compared amisulpride to pla-
cebo in the treatment of PONV (the study of Candiotti 
et al. in patients with no prior prophylaxis, and the study of 
Habib et al. in patients that received up to three standard 
antiemetics).
The details of each study, including number of patients, per-
centage of women participating in the study, baseline PONV 
risk, type of anesthesia as well as prior PONV prophylaxis 
are listed in Table I.
Efficacy of intravenous amisulpride on the  
prevention and treatment of PONV
Three studies investigated intravenous amisulpride in 1-, 
5- and 20-mg (33) or 5-mg doses (34, 35) as prophylaxis of 
PONV in the 24-hour period after surgery. PONV was defined 
as vomiting/retching (emesis) or use of antiemetic rescue. 
The incidence of nausea was a secondary endpoint in all 
3 studies (33-35).
Two studies investigated 5- and 10-mg doses of intra-
venous amisulpride for treatment of established PONV 
(vomiting/retching or episode of nausea that occurred up 
Material and Methods
Search strategy and study selection
This meta-analysis was carried out and reported according 
to the 2009 PRISMA guidelines (30). A systematic literature 
search of MEDLINE (via PubMed), Cochrane Controlled 
Register of Trials (CENTRAL) and ClinicalTrials.gov for ran-
domized, controlled trials, without language or publica-
tion year restrictions, was conducted by two independent 
investigators.
The following search terms were used: (“sultopride” OR “sul-
topride” OR “amisulpride”) AND (“postoperative nausea and 
vomiting” OR (“postoperative” AND “nausea” AND “vomit-
ing” OR “postoperative nausea and vomiting” OR “ponv”).
Randomized, controlled trials, reporting the incidence 
of PONV in patients undergoing general anesthesia with 
an intervention group, receiving amisulpride either as 
prophylaxis or treatment compared to placebo or active 
interventions, were included in the meta-analysis. Criteria 
for exclusion were nonrandomized trials, review articles 
and animal studies.
Data extraction
Study selection, data extraction process as well as risk of 
bias assessment were performed by two independent 
authors (NS and LE). Mendeley Version 1.19.2 was used 
for reference management and duplicate removal. Data 
extraction was performed using a modified Cochrane data 
collection form (31). Risk of bias assessment was deter-
mined by means of the Cochrane Collaboration’s tool. In 
case of a disagreement, a consensus was reached with a 
third investigator. 
The primary endpoint was the incidence of PONV, defined 
as any episode of vomiting/retching or any use of anti-
emetic rescue medication 24 hours after operation or study 
drug administration.
Secondary endpoints included the incidence of rescue anti-
emetic use within the 24-hour postoperative period or 24 
hours after amisulpride administration as well as the inci-
dence of any treatment-emergent AEs (TEAEs), any severe 
AEs and the most frequent TEAE associated with intravenous 
amisulpride administration, such as constipation, flatulence, 
headache, hypotension, anemia, procedural pain, nausea, 
vomiting and pruritus.
Statistical analysis and risk of bias assessment
Random-effects meta-analysis was employed to inte-
grate the data from the studies and calculate the pooled 
effect estimate of intravenous amisulpride on PONV 
and pooled risk estimates for AEs. Effects and AEs were 
expressed as RR (relative risk) with 95% confidence inter-
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Use of rescue medication
Figure 4 shows the use of rescue medication in the first 
24 hours after surgery or study drug administration. 
Amisulpride was associated with a significant decrease in 
rescue medication use as compared to placebo (RR = 0.83; 
95% CI, 0.78-0.88, P < 0.00001).
Safety of intravenous amisulpride
The pooled risk ratios between amisulpride and placebo 
with corresponding 95% CIs for each safety outcome are 
summarized in Table II.
Results of the meta-analysis showed a significantly lower 
risk of postoperative AEs with amisulpride as compared to 
placebo (RR = 0.9; 95% CI, 0.84-0.96; P = 0.008). There was 
no significant difference in the risk of severe AEs (RR = 
0.95; 95% CI, 0.65-1.39, P = 0.79) or potential life-threatening 
AEs (RR = 0.41; 95% CI, 0.13-1.28; P = 0.13) between the two 
groups. Pain (RR = 1.01; 95% CI, 0.90-1.13; P = 0.99) and 
constipation (RR = 0.89; 95% CI, 0.69-1.14; P = 0.35) were 
reported in all 5 trials, showing no significant difference 
to 24 hours after operation and before discharge from the 
hospital, for which the patients requested an antiemetic). 
Both studies then assessed the incidence of PONV, defined 
as emesis or rescue antiemetic use in the 24-hour postop-
erative period, excluding episodes of emesis in the first 30 
minutes (36, 37).
Figure 2 shows the effect of amisulpride 1, 5 and 20 mg on 
preventing PONV within 24 hours after surgery. The pooled 
effect estimates of the meta-analysis of all trials showed a 
significant decreased risk of PONV (RR = 0.78; 95% CI, 0.72-
0.85; P < 0.00001) with amisulpride compared to placebo. 
Subgroup analysis according to dose of the intervention 
suggested no relevant dose effect. However, the number of 
included studies was small.
Figure 3 shows the efficacy of 5 and 10 mg amisulpride 
used to treat established PONV. The meta-analysis favored 
both 5 mg amisulpride (RR = 0.9; 95% CI, 0.83-0.98; P = 
0.02) and 10-mg doses (RR = 0.85; 95% CI, 0.77-0.93; 
P = 0.0004) with an overall RR of 0.87 (95% CI, 0.82-0.93; 
P < 0.0001). There was no difference between 5 and 10 mg 
amisulpride detectable.
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Figure 2. Forest plot of the estimated effect of intravenous amisulpride on prevention of postoperative nausea and vomiting within 
24 hours postoperatively.
Figure 3. Forest plot of the estimated effect of intravenous amisulpride used to treat established postoperative nausea and vomiting within 
the following 24 hours.
between amisulpride and placebo. There was also no 
significant difference in the incidence of flatulence (RR 
= 0.89; 95% CI, 0.69-1.14; P = 0.35), which was reported 
in 4 studies, headache (RR = 1.00; 95% CI, 0.50-1.97; 
P = 0.99) and hypotension (RR = 1.05; 95% CI, 0.69-1.59; 
P = 0.82), both reported in 3 studies, as well as anemia 
(RR = 1.19; 95% CI, 0.7-2.04; P = 0.52) and pruritus (RR = 
0.86; 95% CI, 0.55-1.35; P = 0.52), which were reported 
in 2 trials. The meta-analysis showed no significant 
difference of amisulpride compared to placebo for nau-
sea (RR = 0.93; 95% CI, 0.77-1.13; P = 0.47) and vomiting 
(RR = 0.860; 95% CI, 0.52-1.24; P = 0.32), excluding events 
occurring in the first 24 hours after the end of surgery 
or the study drug administration, reported as a TEAE in 
4 and 2 studies, respectively. Out of all the AEs which 
were reported in just 1 study, only the incidence of 
insomnia/sleep disorder (RR = 2.13; 95% CI, 0.99-4.57; 
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PONV management leads to an overall improvement in 
patients’ well-being after surgery (35-37). The only AEs that 
were observed more frequently in the amisulpride group 
were elevation in serum prolactin levels as well as insomnia. 
Hyperprolactinemia can be explained by amisulpride’s D2 
antagonism on the lactotroph cells in the anterior pituitary, 
leading to a loss of dopamine inhibitory effect on prolactin 
secretion (38). However, the mean prolactin increase after a 
single-dose amisulpride administration did not exceed the 
normal levels in nonpregnant women and did not lead to 
any clinical consequences (34). Insomnia is often linked to 
amisulpride use in a psychiatric setting, where high doses of 
amisulpride (100-1200 mg/day, mean dose 670 mg/day) are 
used in the management of acute exacerbations of schizo-
phrenia, while low doses of amisulpride (< 300 mg/day), 
applied in the treatment of negative symptoms of schizo-
phrenia, showed similar incidence of AEs as compared to 
placebo (19). In the study of Kranke et al., the occurrence 
of insomnia was not found to be dose-dependent and first 
appeared > 48 hours after drug administration, exceeding 
5-fold the half-life of intravenous amisulpride. Therefore, it 
95% CI, 2.75-29.30; P = 0.0003) were found to be significantly 
higher in the amisulpride group as compared to placebo.
Risk of bias
The overall risk of bias in all 5 trials included in the 
meta-analysis was classified by 2 independent investiga-
tors as low based on the report of the studies. All trials were 
funded entirely by Acacia Pharma Ltd., Cambridge, UK. An 
external clinical research organization provided monitoring 
for the trials and external auditing by the FDA took place.
Discussion
The meta-analysis demonstrates that intravenous amisul-
pride effectively reduces the incidence of PONV and use of 
rescue medication in patients undergoing general anesthe-
sia within the first 24 hours postoperatively as well as within 
24 hours after therapeutic use when administered as an 
antiemetic rescue medication.
Amisulpride proved to be a safe antiemetic with lower over-
all incidence of AEs than placebo, suggesting that efficient 
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effect of amisulpride on prolongation of the QT interval is 
dose-dependent. A thorough QT study of Taubel et al. also 
confirmed that intravenous amisulpride dose of 5 mg does 
not lead to prolongation of the QTc interval, while a 40-mg 
supratherapeutic dose was associated with a QTc prolonga-
tion of 23.4 ms from baseline; however, none of the subjects 
experienced an absolute QTcF value of > 500 ms (42).
The 2014 Consensus Guidelines for the management of 
PONV drew attention to combination therapy and multi-
modal approach based on patient’s risk assessment for 
PONV (2). Different pharmacological classes of antiemet-
ics were proven to show an additive effect on the PONV 
risk reduction when combined for the multimodal ther-
apy (43). Since the FDA “black box” warning was issued in 
2001, droperidol, which had been widely used as a first-
line medication for the treatment of PONV, was withdrawn 
from the market in many countries due to safety concerns 
associated with the risk of QT prolongation and TdP, leav-
ing a huge gap in PONV management (44, 45). Amisulpride, 
with its favorable pharmacokinetic profile and a low risk 
remains unclear whether amisulpride contributes to sleep 
disorders after a single-dose administration (24, 33).
Although the use of dopamine antagonists is often associ-
ated with extrapyramidal symptoms, such as bradykinesia, 
tremor, akathisia, Parkinson-like rigidity, tardive dyskinesia 
as well as acute dystonia (24), none of these symptoms were 
observed in any of the trials included for the meta-analysis. 
This data is consistent with prior safety studies in psychiat-
ric use, which showed that amisulpride did not cause more 
extrapyramidal side effects than the placebo (39).
Despite amisulpride being proven to be cardiovascular safe 
at doses ranging from 100 to 1200 mg/day (19), drug over-
dose with doses as high as 4-80 g is associated with QTc 
prolongation, bradycardia, hypotension and a risk of severe 
cardiac arrhythmias, including TdP (40, 41). The included 
studies on low-dose amisulpride did not report any severe 
cardiovascular AEs or any relevant QTc prolongation, how-
ever, only 3 studies (33-35) obtained the patients’ elec-
trocardiogram data postoperatively. Nevertheless, the 
Table II. Meta-analysis of overall adverse events in studies of amisulpride.
Outcome Studies N RR [95% CI] P value  
Blood prolactin increased 1 689 8.97 [2.75, 29.30] 0.0003
P value ≤ 0.05Any TEAE 5 3313 0.90 [0.84, 0.96] 0.0008
Insomnia 1 215 2.13 [0.99, 4.57] 0.05
Any life-threatening AE 5 3313 0.41 [0.13, 1.28] 0.13
P value > 0.05
Pyrexia 1 215 4.72 [0.55, 40.87] 0.16
Abdominal distension 1 689 1.63 [0.78, 3.40] 0.19
Vomitinga 2 1849 0.80 [0.52, 1.24] 0.32
Hypertension 1 215 1.99 [0.49, 8.06] 0.33
Flatulence 4 2166 0.89 [0.69, 1.14] 0.35
Constipation 5 3313 0.91 [0.71, 1.16] 0.43
Nauseaa 4 3098 0.93 [0.77, 1.13] 0.47
Chills 1 1147 1.26 [0.66, 2.40] 0.49
Pruritus 2 1391 0.86 [0.55, 1.35] 0.52
Anemia 2 904 1.19 [0.7, 2.04] 0.52
Hyperglycemia 1 689 0.87 [0.56, 1.35] 0.52
Leukocytosis 1 689 1.13 [0.66, 1.94] 0.66
Dizziness 1 215 0.76 [0.21, 2.73] 0.68
Any SAE 5 3313 0.95 [0.65, 1.39] 0.79
Hypotension 3 2051 1.05 [0.69, 1.59] 0.82
Pain 5 3313 1.01 [0.90, 1.13] 0.89
Hypoproteinemia 1 689 1.04 [0.62, 1.74] 0.9
Headache 3 1606 1.00 [0.50, 1.97] 0.99
Hypocalcemia 1 689 1.00 [0.61, 1.62] 0.99
aExcluding nausea and vomiting within 24 hours after the end of surgery or study drug administration.
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Further to this finding, it is the first time that a new anti-
emetic molecule is tested prior to approval for both the pre-
vention and treatment of PONV. Further trials with active 
comparators must elucidate whether amisulpride’s efficacy 
is comparable to those of other well-established interven-
tions such as ondansetron or dexamethasone. Future trials 
may also help to define the best prophylactic combina-
tion against PONV and—in view of the relatively short 
half-life—whether a repetitive dosing in the postopera-
tive course may further enhance antiemetic action. So far, 
clinical trials with amisulpride have not been performed in 
pediatric patients, which may prove to be a promising tar-
get population.
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ABSTRACT
Introduction: Current therapies of postoperative nausea and vomiting (PONV) are based on
a combination of antiemetics from different pharmacological classes. Dopamine receptor antagonists
are one of the cornerstones of such multimodal antiemetic approach, with droperidol being the best
studied representative of this group. Droperidol’s use has significantly declined after the FDA’s black-
box warning in 2001 due to its QT-prolonging properties. Amisulpride is a promising antiemetic agent
which could fill this gap.
Areas covered: In this review, the authors discuss the pharmacological profile as well as clinical safety and
efficacy of intravenous amisulpride and its relevance in the management of PONV. The article is based on
a Medline, ClinicalTrials.gov, and Cochrane Library search for studies on amisulpride conducted so far.
Expert opinion: Promising clinical results on Barhemsys®, an intravenous formulation of amisulpride,
make it a potential future drug of choice from the dopamine receptor antagonist group, replacing
droperidol after its safety concerns. Amisulpride’s success on the market will mostly be determined by
its cost-effectiveness and it will likely find a brighter use on the US-market, where the black-box
warning led to droperidol’s withdrawal, while in many European countries, droperidol is still being
used as an antiemetic.
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Postoperative nausea and vomiting (PONV), with its multifactorial
etiology, remains a frequent complication linked to anesthesia and
surgical procedures [1]. The general incidence of PONV ranges
between 20% and 30% when balanced anesthesia techniques,
including volatile anesthetics combined with opioids, are used
without pharmacological prophylaxis. However, incidence can
be as high as 80% in patients with multiple risk factors, which
are either patient specific (female gender, history of PONV and/or
motion sickness, nonsmoking status, younger age) or anesthesia
related (use of volatile anesthetics, and/or nitrous oxide, duration
of anesthesia and postoperative opioid use) [1–4]. PONV is char-
acterized by physical signs but also distressing subjective symp-
toms of nausea or retching leading to patients’ dissatisfaction
associated with anesthesia [5,6]. Additionally, it may result in
economic consequences of protracted postoperative stay in the
recovery room, increased nursing time and, finally, readmission to
the hospital following outpatient surgery [7]. In order to minimize
the incidence of PONV, the 2014 Consensus Guidelines suggested
a multimodal approach, consisting of both pharmacological and
non-pharmacological (baseline risk reduction) interventions. Since
none of the single antiemetic agents is fully effective at PONV
management, a combination therapy of drugs acting on different
receptors has been recommended. The main pharmacological
options for PONV include corticosteroids, 5-hydroxytryptamine
(5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor
antagonists, antihistamines (H1-antagonists), anticholinergics, as
well as butyrophenones acting on dopamine-2 receptors [3]. As
antagonists of each of these receptor systems appear to have
similar efficacy and reduce the risk of PONV by approximately one-
fourth (25%), the choice of appropriate agents is primarily
a question of safety and side effects on the one hand and costs
on the other hand [8]. Dopamine antagonist droperidol was
a widely used cost-efficient antiemetic until 2001, when the US
Food and Drug Administration (FDA) issued a black-box warning,
raising safety concerns regarding the risk of QT interval prolonga-
tion (measured from the beginning of QRS complex to the end of
the T-wave; QTc values ≥460 ms in women and ≥390 ms in men,
adjusted to heart rate are considered prolonged) and serious
cardiac arrhythmias, such as torsade de pointes [9–11]. Despite
several authors summarizing existing evidence stating the safety
of the drug in low doses (<2.5 mg) commonly used to prevent or
treat PONV, droperidol is no longer a first-line antiemetic in many
countries [12,13]. Haloperidol, a potential alternative to droperidol,
has been shown to be an effective antiemetic at low doses (0.5 to
2 mg i.m. or i.v.). However, its use is also associated with a risk of
QTc prolongation and its intravenous use as an antiemetic is not
approved by the FDA [3]. As a consequence, the search for new
agents targeting dopamine receptors with a favorable safety pro-
file has recently been intensified [3]. In this context, several older
drugs (typically antipsychotics) were reassessed with amisulpride
emerging as the most interesting candidate.
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2. Overview of the market
Sulpiride, the oldest representative of the substituted benza-
mide group has been available on the market since 1967.
Initially developed for the treatment of gastrointestinal disor-
ders, it soon found its use as an antipsychotic and antidepres-
sant [14]. Nowadays it is commonly prescribed in the
treatment of tics as well as vertigo in many European coun-
tries; however, it has never been marketed in North America
[14–16]. Its derivate, amisulpride, first introduced to the mar-
ket in France over 30 years ago is currently approved in more
than 50 countries worldwide (see Box 1). Indications for its oral
use include both acute and chronic schizophrenia character-
ized by positive and/or negative symptoms [17,18]. In Italy, it is
also approved for the treatment of dysthymia [19].
Recommended daily oral doses are ranging from 50 up to
1200 mg [18]. Since 2010, an extensive clinical research was
carried out to determine amisulpride’s efficacy in both mono-
and combination therapy for PONV.
3. Introduction to the compound
Amisulpride (chemical name: (R, S)-4-Amino-N-[(1-ethyl-2-pyr-
rolidinyl)methyl]-5-ethylsulfonyl-2- methoxybenzamide) is
a substituted benzamide derivate belonging to the group of
atypical antipsychotics [17,18]. It has been marketed as Solian
® since the 1980s (oral form of application) and recently avail-
able as Barhemsys®, a repurposed formula for intravenous
injection.
4. Pharmacodynamics
Amisulpride is a highly selective dopamine D2 (Ki = 2.8 nM), D3
(Ki = 3.2 nM), and 5-HT7a serotonin receptor antagonist, which
shows a low affinity for other dopamine and serotonin recep-
tor subtypes as well as adrenergic, histamine, and cholinergic
receptors [17–22]. Low doses show selectivity for presynaptic
receptors, enhancing dopaminergic activity, whereas higher
doses block postsynaptic dopamine D2 and D3 receptors, inhi-
biting the dopaminergic transmission [20]. These neurochem-
ical features explain amisulpride’s use at lower doses in the
treatment of negative symptoms and at higher doses in the
treatment of positive symptoms of schizophrenia [20,22]. The
compound dosed as a racemate displays polypharmacy –
S-enantiomers target the dopamine D2 and D3 receptors
and thus provide antipsychotic activity while the
R-enantiomer shows a high affinity for the 5-HT7 receptor,
which most likely contributes to antidepressant properties of
amisulpride [21,23].
5. Pharmacokinetics and metabolism
Amisulpride’s pharmacokinetic properties are characterized by
rapid absorption with a biphasic profile, with the first plasma
concentration peak occurring after 1 h (Cmax = 42 ng/mL),
followed by a second peak 4 h after oral administration
(Cmax = 56 ng/mL) with absolute bioavailability of 50% and
a large volume of distribution (5.8 L/kg). Intravenous amisul-
pride is primarily excreted by the renal route in a largely
unchanged form (50%), while the excretion of an oral dose is
mainly to the fecal route (65%) than the renal one (35%) [24].
Hepatic metabolism is minimal and the two metabolites found
in feces and urine are formed by oxidation and deethylation
and are both inactive [25,26]. The terminal plasma elimination
half-life (t½) in healthy population is 7–8 h after intravenous
and 12 h after the oral route of administration. Renal clearance
(17–20 L/h in healthy volunteers) is reduced in patients with
renal insufficiency and correlates linearly with the creatinine
clearance reduction; therefore, in this population, the dose
should be decreased [18,27,28]. Minimal plasma protein bind-
ing (17%), low metabolism, and no inhibition of the cyto-
chrome CYP 450 system’s activity determine amisulpride’s
low potential for drug interactions [29].
Article highlights
● Prophylaxis and treatment of postoperative nausea and vomiting
requires a multimodal approach, including various antiemetics acting
at different receptor sites.
● FDA’s black box warning for droperidol due to QT-prolongation
alienated anaesthesiologists and decreased the use of this potent
dopamine2-antagonist.
● An aqueous solution of amisulpride (Barhemsys(R)), an alternative
D2-antagonist with a superior safety profile will soon be available.
● Depending on economic considerations this drug has the potential to
substitute droperidol within a multimodal antiemetic concept.
Box 1. Drug summary box.
Drug name Amisulpride
Phase Pre-registration
Indication Postoperative nausea and vomiting
Pharmacology
description
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Intravenous amisulpride (1 mg, 5 mg, and 20 mg single doses)
was first tested for PONV monoprophylaxis in a randomized,
double-blind, dose-finding Phase II study of 215 surgical
patients with a moderate to high risk of PONV (see Table 1
for a comprehensive summary of available clinical trials).
Significant reduction of PONV incidence in the 24-h post-
operative period was observed in the 5 mg group (40%, 90%
CI: 28–53%, p = 0.006) as compared to placebo (69%, 90% CI:
57-79%), which was found to be the optimal dose for prevent-
ing PONV with a safety profile similar to placebo [30].
Gan et al. then examined a single 5-mg dose in two con-
current Phase III trials (n = 689) held in Europe and the United
States in patients with a moderate to high risk of PONV; the
pooled data of both those studies confirmed the previous
efficacy and safety results [31].
In 2018, Kranke et al. published a trial that investigated
a 5-mg dose in combination with an antiemetic of a different
pharmacological class (most commonly dexamethasone or
ondansetron) in patients (n = 1147) with a high risk for
PONV. The incidence of PONV or rescue medication use 24
h after surgery was significantly lower in the amisulpride
group (p < 0.001). Again, adverse events did not significantly
differ between the two groups [32].
Candiotti et al. studied amisulpride for the treatment of
established PONV in patients (n = 560) with a low to moderate
risk profile who had not received any prior antiemetic prophy-
laxis. Both 5 mg (p = 0.016) and 10 mg (p = 0.016) amisulpride
doses were superior to placebo in the 24-h period after intra-
venous administration with a comparable incidence of adverse
events in all three groups [33].
The most recent randomized, placebo-controlled, multi-
center Phase III trial of Habib et al. evaluated amisulpride’s
efficacy in the treatment of established PONV after failed
prophylaxis. Seven hundred and two patients with moderate
to high risk of PONV were randomized to receive a single
5 mg, 10 mg, or placebo intravenous amisulpride dose.
Patients who received the 10-mg dose (p = 0.006) experienced
significantly fewer emetic episodes than the placebo group in
the 24 h following the drug administration; however, no sig-
nificant benefit was shown for the 5-mg dose (p = 0.109). The
safety profile was comparable between all three groups [34].
7. Safety and tolerability
Intravenous amisulpride, administered at doses ranging from 5
to 20 mg a day in the management of PONV, was associated
with a lower risk of side effects than the placebo, with insom-
nia and serum prolactin level elevation being the only signifi-
cantly more frequent treatment-emergent adverse events in
the previously reviewed studies [35]. Insomnia first appeared
over 48 h after intervention, which is significantly longer than
the half-life of intravenous amisulpride [30], while the prolac-
tin-elevating effect was small and did not exceed the norm for
non-pregnant women [31]. Therefore, both of these adverse
events appear to be of no clinical significance with a single-
dose treatment. Notably, toxicities usually associated with
dopamine antagonists, including extrapyramidal symptoms
and cardiac arrhythmias, were not observed in any of the
studies. This data is consistent with the experience with intra-
venous amisulpride in the delayed phase of chemotherapy-
induced nausea and vomiting (CINV) [36,37].
Cardiovascular safety of intravenous amisulpride was also
been evaluated in the study of Taubel et al., where a 5-mg
therapeutic dose for PONV had no significant effect on the
QTc interval prolongation. Higher supratherapeutic doses of
40 mg led to QTc prolongation of 23.4 ms from baseline;
however, the absolute QTcF values >500 ms were never
exceeded [38]. Therefore, the prolongation of QTc interval
appears to be dose-dependent, a phenomenon also observed
in CINV trials of intravenous amisulpride [36,37]. The increase
in QTc prolongation from baseline is still 3- and 5-fold lower
than with 4-mg ondansetron and 1-mg droperidol, respec-
tively [39].
This benign safety profile of intravenous amisulpride is
consistent with the studies in the psychiatric population
where much higher oral doses (50–800 mg/day) are often
administered over prolonged periods of time. At low doses
(≤300 mg/day) the incidence of side effects is comparable to
placebo [17]. Higher doses used for acute treatment of schizo-
phrenia were associated with significantly elevated prolactin
levels with the incidence of extrapyramidal side effects similar
to placebo [40].
8. Regulatory affairs
In 2010, a repurposed intravenous formula of amisulpride was
patented. A clinical study program was started under the
investigational drug name APD421 for the indication of pro-
phylaxis and treatment of PONV and CINV [41]. The findings
have undergone a systematic study program that received
a positive evaluation by the FDA. However, in May 2019 the
FDA identified deficiencies of the contract manufacturer of
amisulpride and thus postponed approval of the drug
Barhemsys®. In July 2019, Acacia Pharma Group announced
to resubmit the NDA designating a new supplier of amisul-
pride. In September 2019, the FDA set a PDUFA date for
a decision on Barhemsys® for 26 February 2020.
9. Conclusion
Intravenous amisulpride emerges as a new and effective antie-
metic with an overall safety profile comparable to placebo.
Doses as low as 5 mg used in mono- and combination therapy
effectively prevent PONV within the 24-h postoperative per-
iod. Both 5-mg and 10-mg doses were effective in the treat-
ment of established PONV in patients with no prior
prophylaxis; however, only the 10-mg dose was efficient at
treating PONV after failed prophylaxis. The drug shows no
relevant increase in QT time and thus is superior to other
antiemetics from the group of dopamine receptor antagonists.
Side effects of low doses of amisulpride tested for PONV are
infrequent and benign. In the light of these encouraging
safety issues, the drug has the potential to substitute other
D2-antagonists. However, the final price must be outweighed
against older drugs like droperidol.






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Current therapies for patients with moderate to high risk of
PONV are based on a multimodal approach, including combi-
nation therapy with different pharmacological classes of antie-
metics in order to achieve optimal effects [3]. One class of
antiemetics has lost relevance since a well-established, effec-
tive, and frequently used representative of this group, droper-
idol, was labeled with a black-box warning in 2001. Since then,
the use of droperidol has significantly declined and thus cre-
ated the need for other antiemetics acting on the dopamine
receptor [42]. Another representative of this class, haloperidol,
also received a black-box warning for its QTc prolonging
properties in 2007 [3]. One other potential candidate, meto-
clopramide, also an intensively investigated antiemetic, lost
attractiveness when the European Medicines Agency recom-
mended in 2013 that higher doses needed for the prophylaxis
of PONV should no longer be used as first-line therapy [43].
Other older dopamine receptor antagonists may be effective
but lack systematic investigations on potential side effects
[44]. Amisulpride has the potential to fill this gap. Results
from a clinical study program revealed promising results.
Since the antiemetic properties of the drug known for its D2
/D3 antagonistic effects are not surprising, it is mainly the low
incidence of side effects that make amisulpride an interesting
innovation for the anesthesia community. Not only safety
issues, like the minimal prolongation of QT-time, but also
low incidences of side effects make amisulpride a valuable
addition for a multimodal antiemetic approach. The new
drug, Barhemsys®, will come as a 5 mg i.v. formulation for
the prophylaxis and treatment of ongoing nausea and vomit-
ing. While amisulpride is more likely to find a brighter use as
a new dopamine receptor antagonist on the US market, its
role as an antiemetic in Europe will be limited by droperidol’s
availability in many countries. In the US, the use of droperidol
has decreased since 2001 but this was not only caused by
safety concerns. The major reason for the declined use of
droperidol was its lack of availability since the original manu-
facturer voluntarily withdrew droperidol from the market.
During this period droperidol was not substituted by other
dopamine receptor antagonists. Instead, the use of dexa-
methasone and 5-HT3 antagonists gained popularity, and
many anesthesiologists are not familiar with droperidol any-
more. As of today, droperidol’s cost as a generic substance on
the European market is not relevant; however, amisulpride, as
a newly developed competitor, will lack cost efficiency.
Competition also comes from aprepitant, an NK1-antagonist
that is now available as a generic drug for antineoplastic
chemotherapy and may soon be available for the PONV indi-
cation as well. Despite several pharmacokinetic interactions
due to its metabolism via the CYP3A4 pathway, aprepitant is
a safe drug with a low incidence of side effects [45]. It also has
the potential to complement the pharmacologic armamentar-
ium against PONV. In the view of these emerging possibilities,
blockade of the dopamine receptors still remains
a cornerstone of antiemetic treatment. Amisulpride has the
potential to become the drug of choice in this pharmacologic
group and to substitute other dopamine receptor antagonists,
like droperidol.
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